elacridar has been researched along with Lung Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anderson, R; Jooné, G; Van Rensburg, CE | 1 |
Beijnen, JH; Jewell, RC; Koopman, FJ; Malingré, MM; Paul, EM; Rosing, H; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
1 trial(s) available for elacridar and Lung Neoplasms
Article | Year |
---|---|
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
Topics: Acridines; Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Tetrahydroisoquinolines | 2001 |
1 other study(ies) available for elacridar and Lung Neoplasms
Article | Year |
---|---|
Alpha-tocopherol antagonizes the multidrug-resistance-reversal activity of cyclosporin A, verapamil, GF120918, clofazimine and B669.
Topics: Acridines; Cell Death; Clofazimine; Cyclosporine; Drug Resistance, Multiple; Humans; Isoquinolines; Lung Neoplasms; Tetrahydroisoquinolines; Tumor Cells, Cultured; Verapamil; Vinblastine; Vitamin E | 1998 |